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Background: Lung cancer is one of the most common malignant 
disease and its incidence and mortality continue to increase worldwide. 
The prognosis for patients with non-small cell lung cancer (NSCLC) 
remains extremely poor, thus the analysis of genetic and epigenetic 
alterations in the pathogenesis of lung cancer has extensively re-
searched recently. The present study was undertaken to investigate the 
correlation between HLA phenotype and the prognosis of patients with 
NSCLC.
Methods: We reviewed the medical records of 695 NSCLC patients 
who underwent surgical resection from January 1996 to December 
2005 at University of Occupational and Environmental Health and 
Kitakyushu municipal medical center. Serological typing of HLA 
class I was performed using a microcytotoxicity test of lymphocytes 
or PCR-sequence-speciﬁc oligonucleotides (PCR-SSO). The correla-
tion between HLA phenotypes and clinicopathological features was 
analyzed. The survival curves were calculated by the Kaplan-Meier 
method, and then the comparison of the survival curves was carried 
out using Log-rank test. Multivariate analysis was performed by Cox’s 
proportional hazard model.
Results: The frequency of HLA-A11 in patients with NSCLC was 
higher, whereas the frequencies of B13 and B51 were lower as com-
pared with the control population of each HLA phenotype. The 3-year 
and 5-year overall survival rate of the 695 patients underwent complete 
resection was 72.1% and 64.9%. The 3-year and 5-year disease free 
survival rate (DFI) of entire patients was 62.4% and 54.4%. The cor-
relation between the prognosis (overall survival or DFI) and each HLA 
class I phenotype was analyzed in these patients. The 5-year overall 
survival rate was 73.6% in HLA-A2 positive patients (A2(+)) (n=156) 
and 83.0% in HLA-A2 negative patients (A2(-)) (n=249) at stage I. The 
5-year DFI was 65.7% in A2(+) and 75.4% in A2(-) at stage I. HLA-
A2(+) group at stage I showed the unfavorable prognosis signiﬁcantly 
than A2(-) group both in overall survival (p < 0.05) and DFI (p < 0.05). 
The 5-year overall survival rate was 38.8% in A24(+) (n=181) and 
56.8% in A24(-) (n=109) at stage II and III. Although there was no 
signiﬁcant difference at stage I between HLA-A24(+) and HLA-A24(-) 
groups, HLA-A24(+) group at stage II and III showed poorer prognosis 
than HLA-A24(-) group in overall survival signiﬁcantly (p = 0.01). 
Multivariate analysis was demonstrated that HLA-A2 was the indepen-
dent unfavorable factor that affected overall survival.
Conclusions: Expression of HLA-A2 was considered as one of the 
unfavorable prognostic factors in NSCLC patients at stage I. HLA-
A24(+) group also showed signiﬁcant unfavorable prognosis at stage II 
and III. These results suggested that HLA-A2 and HLA-A24 were the 
prognostic factors in NSCLC patients.
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Prognostic significance of p16INK4A, DAPK and RASSF1A 
promoter hypermethylation in non-small cell lung cancer (NSCLC)
Niklinski, Jacek1 Niklinska, Wieslawa2 Chyczewski, Lech3 Kozlowski, 
Miroslaw1 Pankiewicz, Walentyn3 Naumnik, Wojciech4 Laudanski, 
Wojciech1 Sulewska, Aneta3 Laudanski, Jerzy1 
1 Dept. of Thoracic Surgery, Medical University of Bialystok, Bialystok, 
Poland 2 Dept. of Histology, Medical University of Bialystok, Bialystok, 
Poland 3 Dept. of Clinical Molecular Biology, Medical University of Bi-
alystok, Bialystok, Poland 4 Dept. of Pneumonology, Medical University 
of Bialystok, Bialystok, Poland 
The epigenetic inactivation of tumor suppressor genes may play an im-
portant role in the development and progression of many cancer types, 
including lung cancer. 
Therefore, we investigated association of the aberrant promoter meth-
ylation of p16INK4A, DAPK ((Death-Associated Protein Kinase) and 
RASSF1A (Ras Association Domain Family 1A) genes (by methyla-
tion-speciﬁc PCR), with clinicopathological features and prognosis in 
102 radically resected NSCLCs (62 stage I/II and 40 stage IIIa).
Hypermethylation of the p16INK4A, DAPK and RASSF1A promot-
ers was found in 42 (41%), 38 (37%) and 29 (28%) of the tumor DNA 
samples, respectively. 23 tumors (22%) exhibited hypermethylation of 
all three tumor suppressor genes. Regarding different clinicopathologi-
cal fetures of NSCLCs, there was a signiﬁcant association between 
methylation of the genes and an advanced TNM stage (p=0.05 for 
p16INK4A, p=0.02 for DAPK; p=0.03 for RASSF1A, Fisher’s exact 
test), as well as between adenocarcinoma and squamous cell carcinoma 
for RASSF1A (p= 0.04) and for p16INK4A (p=0.05) hypermethylation. 
Univariate analysis of survival (logrank test) demonstrated a signiﬁcant 
trend of poorer prognosis for patients with methylated p16INK4A, 
DAPK, and RASSF1A genes. Multivariate analysis of survival (Cox 
proportional hazard model) indicated that p16INK4A and DAPK 
promoter hypermethylation was the stronger independent predictor 
factors for early stage I-II (p= 0.04 and p=0.02), whereas RASSF1A 
promoter hypermethylation was the independent prognostic predictor 
for stage IIIa (p=0.04). In conclusion, hypermethylation of p16INK4A 
and DAPK genes is a common abnormality associated with poor 
survival and aggressiveness of early-stage NSCLC, whereas RASSF1A 
methylation is a profound prognostic factor for patients with locally 
advanced NSCLC.
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Background: Cellular retinol binding proteins act as carriers for retinol 
and inﬂuence the trafﬁcking, metabolism, and storage of retinoids in 
the cytoplasm. Alteration of cellular retinol binding protein-1 (CRBP-
1) expression in lung cancer is not known in terms of their association 
with lung carcinogenesis.
